Aptuit to Manufacture Low-Dose NSAID Nanotechnology Platform for Iroko

Iroko Pharmaceuticals and Aptuit have recently declared that Aptuit will provide enhancing production services as Iroko moves to Phase III in its clinical trials of pain medications.

Under the terms of the service contract, Aptuit will deliver nanotechnology formulations for numerous non steroidal anti-inflammatory drugs (NSAIDs). Iroko has completed Phase II trials for all these products. Aptuit will also deliver batch material that complies with the satisfying norms required for product registrations.

Aptuit will utilize the Iroko-owned SoluMatrix technology of Iroko partner, iCeutica. This technology allows production of nano-medications comprising sub-micron, fast-dissolving drug particles.

According to John Vavricka, Iroko’s chief executive officer, the company is following the US Food and Drug Administration regulation that NSAIDs should be deployed at a low effective dose level for very short periods. The nano formulations will help develop NSAIDs at low doses while maintaining efficiency.